IVVD
Get informed when a big investor buys or sells
+ FollowUndervalued by 382.7% based on the discounted cash flow analysis.
| Market cap | $231.41 Million |
|---|---|
| Enterprise Value | $79.72 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.3 |
| Beta | 0.71 |
| Outstanding Shares | 320,435,078 |
| P/E Ratio | -1.99 |
|---|---|
| PEG | -0.98 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1.37 |
| Enterprise Value to EBIT | -0.71 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 0.05 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6885▲ 32.22% |
|---|---|
| Total Calls | 570,400▲ 1.68% |
| Total Puts | 392,700▲ 91.09% |
Holdings and activity of institutional investors.
| Ownership % | 72.70%▼ 0.43% |
|---|---|
| Total Invested | $203.53M▼ 30.83% |
| Investors Holding | 133▼ 13.00% |
No data
Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antib...